Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients

Authors: Jenq-Wen Huang, Chung-Yi Yang, Hon-Yen Wu, Kao-Lang Liu, Chi-Ting Su, Cho-Kai Wu, Jen-Kuang Lee, Chih-Kang Chiang, Hui-Teng Cheng, Yu-Chung Lien, Kuan-Yu Hung

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

In the general population, metabolic syndrome (MetS) is correlated with visceral fat and a risk factor for cardiovascular disease (CVD); however, little is known about the significance of abdominal fat and its association with inflammation and medication use in peritoneal dialysis (PD) patients. We investigated the relationship of visceral fat area (VFA) with C-reactive protein (CRP) levels and medication use in PD patients and followed their clinical outcomes.

Methods

In a prospective study from February 2009 to February 2012, we assessed diabetes mellitus (DM) status, clinical and PD-associated characteristics, medication use, CRP levels, components of MetS, and VFA in 183 PD patients. These patients were categorized into 3 groups based on MetS and DM status: non-MetS (group 1, n = 73), MetS (group 2, n = 65), and DM (group 3, n = 45). VFA was evaluated by computed tomography (CT) and corrected for body mass index (BMI).

Results

Patients in group 1 had smaller VFAs than patients in groups 2 and 3 (3.2 ± 1.8, 4.6 ± 1.9, and 4.9 ± 2.0 cm2/[kg/m2], respectively, P < 0.05) and lower CRP levels (0.97 ± 2.31, 1.27 ± 2.57, and 1.11 ± 1.35 mg/dL, respectively, P < 0.05). VFA increased with the number of criteria met for MetS. After adjusting for age, body weight, and sex, CRP and albumin levels functioned as independent positive predictors of VFA; on other hand, the use of renin-angiotensin system blockers was inversely correlated with VFA in PD patients without DM. In the survival analysis, DM patients (group 3) had the poorest survival among the 3 groups, but no significant differences were found between groups 1 and 2.

Conclusion

This study showed that VFA and MetS are associated with CRP levels but cannot predict survival in PD patients without DM. The complex relationship of nutritional parameters to VFA and MetS may explain these results. The type of antihypertensive medication used was also associated with the VFA. The mechanisms behind these findings warrant further investigation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lear SA, Humphries KH, Kohli S, Frohlich JJ, Birmingham CL, Mancini GB: Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: results of the Multicultural Community Health Assessment Trial (M-CHAT). Stroke. 2007, 38 (9): 2422-2429. 10.1161/STROKEAHA.107.484113.CrossRefPubMed Lear SA, Humphries KH, Kohli S, Frohlich JJ, Birmingham CL, Mancini GB: Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: results of the Multicultural Community Health Assessment Trial (M-CHAT). Stroke. 2007, 38 (9): 2422-2429. 10.1161/STROKEAHA.107.484113.CrossRefPubMed
2.
go back to reference Ditomasso D, Carnethon MR, Wright CM, Allison MA: The associations between visceral fat and calcified atherosclerosis are stronger in women than men. Atherosclerosis. 2010, 208 (2): 531-536. 10.1016/j.atherosclerosis.2009.08.015.CrossRefPubMed Ditomasso D, Carnethon MR, Wright CM, Allison MA: The associations between visceral fat and calcified atherosclerosis are stronger in women than men. Atherosclerosis. 2010, 208 (2): 531-536. 10.1016/j.atherosclerosis.2009.08.015.CrossRefPubMed
3.
go back to reference Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, Tafuri D, Lombardi G, Colao A, Orio F: Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008, 23 (1): 153-159.CrossRefPubMed Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, Tafuri D, Lombardi G, Colao A, Orio F: Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod. 2008, 23 (1): 153-159.CrossRefPubMed
4.
go back to reference Konishi K, Nakano S, Seto H, Tsuda S, Koya D: Carotid atherosclerosis mediated by visceral adiposity and adipocytokines in type 2 diabetic subjects. Diabetes Res Clin Pract. 2009, 85 (2): 171-178. 10.1016/j.diabres.2009.04.021.CrossRefPubMed Konishi K, Nakano S, Seto H, Tsuda S, Koya D: Carotid atherosclerosis mediated by visceral adiposity and adipocytokines in type 2 diabetic subjects. Diabetes Res Clin Pract. 2009, 85 (2): 171-178. 10.1016/j.diabres.2009.04.021.CrossRefPubMed
5.
go back to reference Kishida K, Funahashi T, Matsuzawa Y, Shimomura I: Visceral adiposity as a target for the management of the metabolic syndrome. Ann Med. 2012, 44 (3): 233-241. 10.3109/07853890.2011.564202.CrossRefPubMed Kishida K, Funahashi T, Matsuzawa Y, Shimomura I: Visceral adiposity as a target for the management of the metabolic syndrome. Ann Med. 2012, 44 (3): 233-241. 10.3109/07853890.2011.564202.CrossRefPubMed
6.
go back to reference Mafra D, Guebre-Egziabher F, Fouque D: Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant. 2008, 23 (8): 2461-2466. 10.1093/ndt/gfn053.CrossRefPubMed Mafra D, Guebre-Egziabher F, Fouque D: Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant. 2008, 23 (8): 2461-2466. 10.1093/ndt/gfn053.CrossRefPubMed
7.
go back to reference Huang JW, Lien YC, Wu HY, Yen CJ, Pan CC, Hung TW, Su CT, Chiang CK, Cheng HT, Hung KY: Lean body mass predicts long-term survival in Chinese patients on peritoneal dialysis. PLoS One. 2013, 8 (1): e54976-10.1371/journal.pone.0054976.PubMedCentralCrossRefPubMed Huang JW, Lien YC, Wu HY, Yen CJ, Pan CC, Hung TW, Su CT, Chiang CK, Cheng HT, Hung KY: Lean body mass predicts long-term survival in Chinese patients on peritoneal dialysis. PLoS One. 2013, 8 (1): e54976-10.1371/journal.pone.0054976.PubMedCentralCrossRefPubMed
8.
go back to reference Odamaki M, Furuya R, Ohkawa S, Yoneyama T, Nishikino M, Hishida A, Kumagai H: Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant. 1999, 14 (10): 2427-2432. 10.1093/ndt/14.10.2427.CrossRefPubMed Odamaki M, Furuya R, Ohkawa S, Yoneyama T, Nishikino M, Hishida A, Kumagai H: Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant. 1999, 14 (10): 2427-2432. 10.1093/ndt/14.10.2427.CrossRefPubMed
9.
go back to reference Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, Maruyama Y, Odamaki M: Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant. 2011, 26 (6): 1967-1976. 10.1093/ndt/gfq652.CrossRefPubMed Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, Maruyama Y, Odamaki M: Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant. 2011, 26 (6): 1967-1976. 10.1093/ndt/gfq652.CrossRefPubMed
10.
go back to reference Miyamoto T, Rashid Qureshi A, Heimburger O, Barany P, Carrero K, Sjoberg B, Lindholm B, Stenvinkel P, Carrero JJ: Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol. 2011, 6 (12): 2785-2791. 10.2215/CJN.02320311.PubMedCentralCrossRefPubMed Miyamoto T, Rashid Qureshi A, Heimburger O, Barany P, Carrero K, Sjoberg B, Lindholm B, Stenvinkel P, Carrero JJ: Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol. 2011, 6 (12): 2785-2791. 10.2215/CJN.02320311.PubMedCentralCrossRefPubMed
11.
go back to reference Lee MJ, Shin DH, Kim SJ, Oh HJ, Yoo DE, Kim JK, Park JT, Han SH, Kang SW, Choi KH: Visceral fat thickness is associated with carotid atherosclerosis in peritoneal dialysis patients. Obesity (Silver Spring). 2012, 20 (6): 1301-1307. 10.1038/oby.2011.245.CrossRef Lee MJ, Shin DH, Kim SJ, Oh HJ, Yoo DE, Kim JK, Park JT, Han SH, Kang SW, Choi KH: Visceral fat thickness is associated with carotid atherosclerosis in peritoneal dialysis patients. Obesity (Silver Spring). 2012, 20 (6): 1301-1307. 10.1038/oby.2011.245.CrossRef
12.
go back to reference Wu HY, Hung KY, Huang TM, Hu FC, Peng YS, Huang JW, Lin SL, Chen YM, Chu TS, Tsai TJ: Safety issues of long-term glucose load in patients on peritoneal dialysis--a 7-year cohort study. PLoS One. 2012, 7 (1): e30337-10.1371/journal.pone.0030337.PubMedCentralCrossRefPubMed Wu HY, Hung KY, Huang TM, Hu FC, Peng YS, Huang JW, Lin SL, Chen YM, Chu TS, Tsai TJ: Safety issues of long-term glucose load in patients on peritoneal dialysis--a 7-year cohort study. PLoS One. 2012, 7 (1): e30337-10.1371/journal.pone.0030337.PubMedCentralCrossRefPubMed
13.
go back to reference Wu HY, Hung KY, Huang JW, Chen YM, Tsai TJ, Wu KD: Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis. Am J Nephrol. 2008, 28 (5): 765-771. 10.1159/000128608.CrossRefPubMed Wu HY, Hung KY, Huang JW, Chen YM, Tsai TJ, Wu KD: Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis. Am J Nephrol. 2008, 28 (5): 765-771. 10.1159/000128608.CrossRefPubMed
14.
go back to reference Wu HY, Hung KY, Hu FC, Chen YM, Chu TS, Huang JW, Wu KD, Tsai TJ: Risk factors for high dialysate glucose use in PD patients--a retrospective 5-year cohort study. Perit Dial Int. 2010, 30 (4): 448-455. 10.3747/pdi.2009.00063.CrossRefPubMed Wu HY, Hung KY, Hu FC, Chen YM, Chu TS, Huang JW, Wu KD, Tsai TJ: Risk factors for high dialysate glucose use in PD patients--a retrospective 5-year cohort study. Perit Dial Int. 2010, 30 (4): 448-455. 10.3747/pdi.2009.00063.CrossRefPubMed
15.
go back to reference Cheng SC, Chu TS, Huang KY, Chen YM, Chang WK, Tsai TJ, Wu KD: Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int. 2001, 21 (3): 282-289.PubMed Cheng SC, Chu TS, Huang KY, Chen YM, Chang WK, Tsai TJ, Wu KD: Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int. 2001, 21 (3): 282-289.PubMed
16.
go back to reference Chen HY, Kao TW, Huang JW, Chu TS, Wu KD: Correlation of metabolic syndrome with residual renal function, solute transport rate and peritoneal solute clearance in chronic peritoneal dialysis patients. Blood Purif. 2008, 26 (2): 138-144. 10.1159/000113506.CrossRefPubMed Chen HY, Kao TW, Huang JW, Chu TS, Wu KD: Correlation of metabolic syndrome with residual renal function, solute transport rate and peritoneal solute clearance in chronic peritoneal dialysis patients. Blood Purif. 2008, 26 (2): 138-144. 10.1159/000113506.CrossRefPubMed
17.
go back to reference Li PK, Kwan BC, Ko GT, Chow KM, Leung CB, Szeto CC: Treatment of metabolic syndrome in peritoneal dialysis patients. Perit Dial Int. 2009, 29 (Suppl 2): S149-S152.PubMed Li PK, Kwan BC, Ko GT, Chow KM, Leung CB, Szeto CC: Treatment of metabolic syndrome in peritoneal dialysis patients. Perit Dial Int. 2009, 29 (Suppl 2): S149-S152.PubMed
18.
go back to reference Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis. 2004, 43 (6): 1047-1055. 10.1053/j.ajkd.2004.02.017.CrossRefPubMed Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis. 2004, 43 (6): 1047-1055. 10.1053/j.ajkd.2004.02.017.CrossRefPubMed
19.
go back to reference Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, Ohnishi A, Shintaku-Kubota M, Mabuchi H, Yamagishi M, Kobayashi J: Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res. 2007, 30 (12): 1205-1210. 10.1291/hypres.30.1205.CrossRefPubMed Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, Ohnishi A, Shintaku-Kubota M, Mabuchi H, Yamagishi M, Kobayashi J: Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res. 2007, 30 (12): 1205-1210. 10.1291/hypres.30.1205.CrossRefPubMed
20.
go back to reference Nakagawa N, Yao N, Hirayama T, Ishida M, Ishida H, Wada A, Fujino T, Saijo Y, Kikuchi K, Hasebe N: Potential impact of renin-angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients. Hypertens Res. 2011, 34 (5): 592-598. 10.1038/hr.2010.282.CrossRefPubMed Nakagawa N, Yao N, Hirayama T, Ishida M, Ishida H, Wada A, Fujino T, Saijo Y, Kikuchi K, Hasebe N: Potential impact of renin-angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients. Hypertens Res. 2011, 34 (5): 592-598. 10.1038/hr.2010.282.CrossRefPubMed
21.
go back to reference Deedwania P: Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens (Greenwich). 2011, 13 (1): 52-59. 10.1111/j.1751-7176.2010.00386.x.CrossRef Deedwania P: Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens (Greenwich). 2011, 13 (1): 52-59. 10.1111/j.1751-7176.2010.00386.x.CrossRef
22.
go back to reference Chan DC, Watts GF: Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother. 2011, 12 (1): 13-30. 10.1517/14656566.2010.502529.CrossRefPubMed Chan DC, Watts GF: Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother. 2011, 12 (1): 13-30. 10.1517/14656566.2010.502529.CrossRefPubMed
23.
go back to reference Gotoh H, Gohda T, Tanimoto M, Gotoh Y, Horikoshi S, Tomino Y: Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant. 2009, 24 (11): 3474-3480. 10.1093/ndt/gfp290.CrossRefPubMed Gotoh H, Gohda T, Tanimoto M, Gotoh Y, Horikoshi S, Tomino Y: Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant. 2009, 24 (11): 3474-3480. 10.1093/ndt/gfp290.CrossRefPubMed
24.
go back to reference Dobiasova M, Frohlich J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001, 34 (7): 583-588. 10.1016/S0009-9120(01)00263-6.CrossRefPubMed Dobiasova M, Frohlich J: The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001, 34 (7): 583-588. 10.1016/S0009-9120(01)00263-6.CrossRefPubMed
25.
go back to reference National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002, 106 (25): 3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002, 106 (25): 3143-3421.
26.
go back to reference Lin CC, Chen CC, Kung PT, Li CI, Yang SY, Liu CS, Lin WY, Lee CC, Li TC, Kardia SL: Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the taichung diabetes study. Cardiovasc Diabetol. 2012, 11: 131-10.1186/1475-2840-11-131.PubMedCentralCrossRefPubMed Lin CC, Chen CC, Kung PT, Li CI, Yang SY, Liu CS, Lin WY, Lee CC, Li TC, Kardia SL: Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the taichung diabetes study. Cardiovasc Diabetol. 2012, 11: 131-10.1186/1475-2840-11-131.PubMedCentralCrossRefPubMed
27.
go back to reference Kim CS, Choi JS, Park JW, Bae EH, Ma SK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Kim SW: Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction. Cardiovasc Diabetol. 2011, 10: 95-10.1186/1475-2840-10-95.PubMedCentralCrossRefPubMed Kim CS, Choi JS, Park JW, Bae EH, Ma SK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Kim SW: Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction. Cardiovasc Diabetol. 2011, 10: 95-10.1186/1475-2840-10-95.PubMedCentralCrossRefPubMed
28.
go back to reference Bhardwaj S, Misra A, Misra R, Goel K, Bhatt SP, Rastogi K, Vikram NK, Gulati S: High prevalence of abdominal, intra-abdominal and subcutaneous adiposity and clustering of risk factors among urban Asian Indians in North India. PLoS One. 2011, 6 (9): e24362-10.1371/journal.pone.0024362.PubMedCentralCrossRefPubMed Bhardwaj S, Misra A, Misra R, Goel K, Bhatt SP, Rastogi K, Vikram NK, Gulati S: High prevalence of abdominal, intra-abdominal and subcutaneous adiposity and clustering of risk factors among urban Asian Indians in North India. PLoS One. 2011, 6 (9): e24362-10.1371/journal.pone.0024362.PubMedCentralCrossRefPubMed
29.
go back to reference Bazanelli AP, Kamimura MA, Manfredi SR, Draibe SA, Cuppari L: Usefulness of waist circumference as a marker of abdominal adiposity in peritoneal dialysis: a cross-sectional and prospective analysis. Nephrol dialy trans off publ European Dialy Trans Assoc European Renal Assoc. 2012, 27 (2): 790-795. Bazanelli AP, Kamimura MA, Manfredi SR, Draibe SA, Cuppari L: Usefulness of waist circumference as a marker of abdominal adiposity in peritoneal dialysis: a cross-sectional and prospective analysis. Nephrol dialy trans off publ European Dialy Trans Assoc European Renal Assoc. 2012, 27 (2): 790-795.
30.
go back to reference Ruan X, Guan Y: Metabolic syndrome and chronic kidney disease. J Diabetes. 2009, 1 (4): 236-245. 10.1111/j.1753-0407.2009.00042.x.CrossRefPubMed Ruan X, Guan Y: Metabolic syndrome and chronic kidney disease. J Diabetes. 2009, 1 (4): 236-245. 10.1111/j.1753-0407.2009.00042.x.CrossRefPubMed
31.
go back to reference Guzik TJ, Mangalat D, Korbut R: Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol. 2006, 57 (4): 505-528.PubMed Guzik TJ, Mangalat D, Korbut R: Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol. 2006, 57 (4): 505-528.PubMed
32.
go back to reference Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001, 12 (7): 1549-1557.PubMed Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001, 12 (7): 1549-1557.PubMed
33.
go back to reference Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P, Lindholm B, Carrero JJ: Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant. 2010, 25 (2): 562-568. 10.1093/ndt/gfp492.CrossRefPubMed Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P, Lindholm B, Carrero JJ: Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant. 2010, 25 (2): 562-568. 10.1093/ndt/gfp492.CrossRefPubMed
34.
go back to reference Lu Q, Cheng LT, Wang T, Wan J, Liao LL, Zeng J, Qin C, Li KJ: Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J renal nutri off j Council Renal Nutri Nat Kidney Found. 2008, 18 (6): 495-502. 10.1053/j.jrn.2008.05.006.CrossRef Lu Q, Cheng LT, Wang T, Wan J, Liao LL, Zeng J, Qin C, Li KJ: Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J renal nutri off j Council Renal Nutri Nat Kidney Found. 2008, 18 (6): 495-502. 10.1053/j.jrn.2008.05.006.CrossRef
35.
go back to reference Wu CK, Huang YT, Lin HH, Yang CY, Lien YC, Lee JK, Huang JW, Hung KY: Dissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients. PLoS One. 2013, 8 (5): e62722-10.1371/journal.pone.0062722.PubMedCentralCrossRefPubMed Wu CK, Huang YT, Lin HH, Yang CY, Lien YC, Lee JK, Huang JW, Hung KY: Dissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients. PLoS One. 2013, 8 (5): e62722-10.1371/journal.pone.0062722.PubMedCentralCrossRefPubMed
36.
go back to reference Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K: Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism. 2009, 58 (5): 708-713. 10.1016/j.metabol.2009.01.013.CrossRefPubMed Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K: Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism. 2009, 58 (5): 708-713. 10.1016/j.metabol.2009.01.013.CrossRefPubMed
37.
go back to reference McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010, 362 (16): 1477-1490.CrossRefPubMed McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010, 362 (16): 1477-1490.CrossRefPubMed
38.
go back to reference Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004, 292 (18): 2227-2236. 10.1001/jama.292.18.2227.CrossRefPubMed Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004, 292 (18): 2227-2236. 10.1001/jama.292.18.2227.CrossRefPubMed
39.
go back to reference Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis. 2007, 49 (5): 581-591. 10.1053/j.ajkd.2007.02.277.CrossRefPubMed Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis. 2007, 49 (5): 581-591. 10.1053/j.ajkd.2007.02.277.CrossRefPubMed
40.
go back to reference Perl J, Bargman JM: The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis. 2009, 53 (6): 1068-1081. 10.1053/j.ajkd.2009.02.012.CrossRefPubMed Perl J, Bargman JM: The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis. 2009, 53 (6): 1068-1081. 10.1053/j.ajkd.2009.02.012.CrossRefPubMed
Metadata
Title
Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients
Authors
Jenq-Wen Huang
Chung-Yi Yang
Hon-Yen Wu
Kao-Lang Liu
Chi-Ting Su
Cho-Kai Wu
Jen-Kuang Lee
Chih-Kang Chiang
Hui-Teng Cheng
Yu-Chung Lien
Kuan-Yu Hung
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-86

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine